However, semaglutide starts to come off patent in several countries in early 2026, including India, which is both the worlds largest sugar consumer and also home to approximately 135 million pre-diabetic adults
Moreover, in subjects with diabetes who were at high risk of cardiovascular events, treatment with GLP-1R agonists based on the structure of endogenous GLP-1, namely liraglutide, semaglutide, albiglutide, and dulaglutide, has demonstrated reductions in major adverse cardiovascular events (MACEs) that appear to be unrelated to the glycemic effects of these agents (1316)
Others want enhanced formulations with glycine and B12
Glucagon-like peptide-1 or GLP-1 antagonists are, however, a class of medications that mainly manage blood sugar levels in people with Type 2 diabetes
Patients with connective tissue disorders, a history of bariatric surgery, or significant prior weight cycling may experience more pronounced laxity